Clinical trial
Atazanavir Versus Lopinavir/Ritonavir (LPV/RTV) in Patients Who Have Not Had…
NCT00028301 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00028301 |
|---|---|
| Title | Atazanavir Versus Lopinavir/Ritonavir (LPV/RTV) in Patients Who Have Not Had Success With Protease Inhibitor-Containing HAART Regimen(s) |
| Official title | A Randomized Open-label Study of the Antiviral Efficacy and Safety of Atazanavir Versus Lopinavir/Ritonavir(LPV/RTV), Each in Combination With Two Nucleosides in Subjects Who Have Experienced Virologic Failure With Prior Protease Inhibitor-Containing HAART Regimen(s) |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Atazanavir, Lopinavir/Ritonavir |
| Start date | Feb 1, 2001 |
| Primary completion | Sep 1, 2003 |
| Completion | Sep 1, 2003 |
| First posted | Dec 21, 2001 |
| Last update posted | Sep 13, 2010 |
| Countries | Argentina, Australia, Belgium, Brazil, Canada, Chile, France, Italy, Mexico, Netherlands, Peru, Puerto Rico and 3 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: